IMM 3.45% 30.0¢ immutep limited

nomura report target 32c, page-27

  1. 701 Posts.
    From memory it was something like 4 months difference in median OS.
    But that was skewed by some of the control arm being given Frovenge (Frozen Provenge) once they progressed.
    A subsequent study taking that into account showed the real median benefit to be over 7 months.
    However, FDA approval for the label still states 4 months.

    This is something that CVac may have to deal with, due to their CAN-003X study. One assumes that the FDA are confident in the trial design of CANVAS that they would allow the secondary endpoint of CAN-003 to be muddied.
    Suggesting that CAN-003 may be somewhat of a formality.
    What are your views?
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
30.0¢
Change
0.010(3.45%)
Mkt cap ! $435.7M
Open High Low Value Volume
29.0¢ 30.5¢ 28.8¢ $574.2K 1.921M

Buyers (Bids)

No. Vol. Price($)
11 461775 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 100000 1
View Market Depth
Last trade - 16.10pm 07/08/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.